Drug-drug Interaction Study of FYU-981 and Oxaprozin

Phase 1 Completed 12 enrolled Mochida Pharmaceutical Company, Ltd. Fuji Yakuhin Co., Ltd. · collab

Non-randomizedSingle-groupOpen-labelBasic science

Summary

This is an open-label, 2-period add-on study to assess the drug-drug interaction between FYU-981 and oxaprozin. The purpose of this study is to investigate the pharmacokinetics of each period in a single administration of FYU-981 and concomitant administration of FYU-981 with oxaprozin at steady -state in healthy volunteers.

Timeline

Start: 2017-11-02
Primary completion: 2017-12-05
Completion: 2017-12-05

Publications

Furihata K, Nagasawa K, Hagino A, Kumagai Y. A drug-drug interaction study of a novel, selective urate reabsorption inhibitor dotinurad and the non-steroidal anti-inflammatory drug oxaprozin in healthy adult males. Clin Exp Nephrol. 2020 Mar;24(Suppl 1):36-43. doi: 10.1007/s10157-020-01855-2. Epub 2020 Feb 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dotinurad	Small molecule	4 mg	—
Subject	Oxaprozin	Small molecule	—	—

Indications

No indication recorded.